Moderna, Inc. (MRNA) Return on equity 2018–2025
Moderna, Inc. (MRNA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.6%FY2025 · since FY2018: -25.1% → -32.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32.6% | +0.0 pp |
| FY2024 | -32.7% | +1.4 pp |
| FY2023 | -34.0% | -77.8 pp |
| FY2022 | 43.7% | -42.5 pp |
| FY2021 | 86.3% | +115.4 pp |
| FY2020 | -29.2% | +14.6 pp |
| FY2019 | -43.7% | -18.6 pp |
| FY2018 | -25.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MRNA financial trends
MRNA RevenueMRNA Net incomeMRNA Net marginMRNA Gross profitMRNA Gross marginMRNA Operating incomeMRNA Operating marginMRNA Operating cash flowMRNA Free cash flowMRNA Capital expendituresMRNA Stock buybacksMRNA Dividends paidMRNA Total assetsMRNA Total liabilitiesMRNA Shareholders’ equityMRNA overview →